On 11 June 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Wegovy tablets, oral semaglutide, for weight management in the UK.
It's the first oral GLP-1 receptor agonist licensed specifically for weight loss anywhere in Europe. And it means people who can't or don't want to use injections now have a fully licensed alternative.
This guide explains exactly how the tablet works, what the OASIS 4 trial found, how the dosing schedule works and what the approval means in practice if you're considering treatment.
Same active ingredient as the Wegovy injection, no needles. The trade-off is a strict morning routine.
You can also read the other articles in our Wegovy tablets series:
What are Wegovy semaglutide tablets?
Wegovy semaglutide tablets are a once-daily weight loss tablet containing semaglutide, the same active ingredient as Wegovy. They're also known as the Wegovy pill, and they're made by Novo Nordisk, the Danish pharmaceutical company behind the original Wegovy pen.
What sets them apart from older oral semaglutide products is the dose and what they're licensed for. Wegovy tablets go up to 25mg a day, much higher than Rybelsus, an earlier oral semaglutide licensed only for type 2 diabetes at doses up to 9mg.
That higher dose is needed because your body absorbs very little semaglutide by mouth. A much larger amount has to be taken to reach the blood levels needed for meaningful weight loss.
The US Food and Drug Administration (FDA) approved semaglutide tablets in December 2025, and they launched in the US in January 2026. That made them the first oral GLP-1 receptor agonist licensed specifically for weight management in the world.1
The MHRA then approved Wegovy semaglutide tablets on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 for weight management.
How do Wegovy semaglutide tablets work?
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after eating.
It tells your brain you're full, slows how quickly food leaves your stomach, and helps regulate your blood sugar by triggering insulin release when glucose rises.
By mimicking this hormone at a treatment dose, semaglutide has several effects that support weight loss:
- Lower appetite - semaglutide acts on the parts of your brain that control hunger and reward, reducing the urge to eat and the appeal of high-calorie foods
- Slower stomach emptying - food leaves your stomach more slowly, so you feel full for longer after meals
- Steadier blood sugar - by triggering insulin release when your blood sugar rises, semaglutide helps prevent the spikes and crashes that can drive cravings
- Less "food noise" - many people on semaglutide say they have fewer intrusive thoughts about food and eating, an effect researchers have noticed but are still studying
Together, these make it easier to eat less, without the constant hunger that makes calorie cutting so hard to keep up.
Many people notice their appetite change within the first few weeks, before the scales move much.
What is SNAC and why does it matter?
Why do semaglutide tablets need a fasting routine, and why is the dose so much higher than the injection? It comes down to a molecule called SNAC (salcaprozate sodium).
Semaglutide is a peptide, and peptides are normally broken down by stomach acid and digestive enzymes before they can be absorbed. Without protection, almost none of an oral dose would reach your bloodstream.
SNAC tackles this in two ways. It raises the pH right around the tablet in your stomach, protecting semaglutide from acid. And it temporarily makes your stomach lining more permeable, so semaglutide can pass through into your circulation.2
Even with SNAC, only around 1% or less of each tablet dose is absorbed, compared with the injection. That's why the tablet dose (25mg) looks so much higher than the injection maintenance dose (2.4mg for standard Wegovy, 7.2mg for the higher-dose version). The bigger dose makes up for the lower absorption, so you still reach effective blood levels.
SNAC is also why the fasting rule matters so much. Food disrupts both the pH effect and the window SNAC opens in your stomach lining. Taking the tablet with, or too soon after, food significantly reduces absorption, potentially to the point where it has little effect.
Water only, up to 120ml. Coffee, tea and juice all count as "anything else" and will affect absorption.
How effective are Wegovy semaglutide tablets for weight loss?
The key evidence comes from the OASIS 4 trial, a phase 3 randomised controlled trial. It involved 307 adults without diabetes, with a BMI of 30 or above (or 27 or above with at least one weight-related health condition). They took either oral semaglutide 25mg or a placebo for 64 weeks, alongside lifestyle support.3
The results were significant. Among people who stuck with treatment, oral semaglutide 25mg led to an average weight loss of 16.6%, compared with 2.7% on placebo. Including everyone, whether or not they completed treatment, the average was 13.6%, compared with 2.2% on placebo.3
To put that in practical terms, someone starting at 100kg who stuck fully with treatment would, on average, lose around 16.6kg over 64 weeks. Around one in three people in that group lost at least 20% of their body weight.
OASIS 4 also found improvements in blood sugar, waist size, blood pressure and other markers linked to heart and metabolic health. That's in line with the wider evidence for semaglutide.
Wegovy semaglutide pill vs the Wegovy injection
The Wegovy pill and the Wegovy injection contain the same active ingredient and work in the same way. The differences are practical, not in how the medicine works.
You take the injection once a week, at any time of day, with or without food. The pens are stored in the fridge before first use.
You take the tablet once a day on a completely empty stomach, with no more than 120ml of plain water, followed by a 30-minute wait. The injection gets into your bloodstream more predictably because it bypasses your stomach entirely. The tablet is affected by anything that disrupts absorption: food, other medicines, even too much water.
In terms of results, the injection has a modest edge in average weight loss. The STEP 1 trial of Wegovy 2.4mg injections found average weight loss of around 14.9% over 68 weeks.4
For the higher 7.2mg injection, the STEP UP trial reported an average of 20.7% over 72 weeks among people who stuck with treatment.5 The OASIS 4 tablet results (16.6% for those who stuck with it, 13.6% overall) sit in a similar range to the standard 2.4mg injection, though the trials were designed differently and can't be directly compared.
The biggest practical advantage of the tablet is that there are no needles at all. If you have a needle phobia or injection anxiety, the tablet gives you access to semaglutide for weight management in a way that wasn't available before.
Are Wegovy semaglutide tablets the same as Rybelsus?
No, and the difference matters. Rybelsus and Wegovy semaglutide tablets both contain oral semaglutide and both use SNAC. But they're separate products, with different licences, different doses and different approved uses in the UK.
Rybelsus is licensed in the UK to treat type 2 diabetes. Since its reformulation in September 2025, its doses range from 1.5mg to 9mg a day. It isn't licensed for weight management, and it hasn't been studied at high enough doses for weight loss.
Wegovy semaglutide tablets are made specifically for weight management, at doses up to 25mg a day. That higher dose is needed to reach the semaglutide levels required for clinically meaningful weight loss. Rybelsus at its 9mg maximum wouldn't be expected to give the same results.
The names sometimes get used interchangeably online, but clinically they're not interchangeable. If you want semaglutide for weight management, use the product licensed and studied for that, not Rybelsus used off-label.
Dosage and how to take Wegovy semaglutide tablets
Semaglutide tablets follow a gradual dose increase schedule. You start low and go up every 30 days, which gives your body time to adjust and reduces the chance of digestive side effects in the early weeks.
The approved schedule is:
- Days 1 to 30: 1.5mg once daily
- Days 31 to 60: 4mg once daily
- Days 61 to 90: 9mg once daily
- Day 91 onwards: 25mg once daily (maintenance dose)
You then stay on 25mg once a day for the rest of your treatment. If 25mg doesn't agree with you, talk to your clinician about your options.
How you take it matters, because absorption depends on consistent conditions:
- Take the tablet on an empty stomach, first thing in the morning before breakfast
- Use only a small sip of plain water to swallow it, not a full glass
- Swallow it whole, and do not crush, split or chew it
- Wait at least 30 minutes before eating, drinking anything other than plain water, or taking any other oral medicine
Both parts matter: the empty stomach before your dose and the 30-minute wait afterwards. Skipping either reduces how much semaglutide is absorbed, potentially to the point where the dose has little effect.
Do not crush, split or chew Wegovy tablets. Swallow them whole with a small sip of water.
Side effects of Wegovy semaglutide tablets
The side effects of semaglutide tablets are broadly similar to the injection, with digestive effects being the most common.
In the OASIS 4 trial, 46.6% of people on semaglutide reported nausea, compared with 18.6% on placebo. Vomiting affected 30.9% of people on semaglutide, compared with 5.9% on placebo.3
Nausea rates were similar to the STEP 1 injection trial, where around 44% of people reported it, though vomiting was a little more common with the tablet.4
Despite those numbers, side effects were mostly mild to moderate, and most settled over time. Around 6.9% of people on semaglutide stopped because of side effects, compared with 5.9% on placebo. That small difference suggests the side effects were manageable for most people.3
The most commonly reported side effects include:
- Nausea - very common; most frequent while your dose is going up, and usually improves on the maintenance dose
- Vomiting - very common in the early weeks, and usually short-lived
- Diarrhoea - common
- Constipation - common, and it can last longer than other digestive effects
- Stomach pain - common
Eating smaller meals, avoiding fatty or spicy foods and not lying down straight after eating can all help with digestive side effects.
Don't speed up the dose increases. If a dose doesn't agree with you, staying on it for longer before moving up is better than stopping treatment.
More serious but less common side effects include pancreatitis and gallbladder problems. If you get severe tummy pain, especially pain that spreads to your back, get urgent medical advice.
Severe tummy pain that spreads to your back needs urgent medical help. It can be a sign of pancreatitis.
Wegovy semaglutide tablets and the contraceptive pill
This is a common question, and the evidence is more reassuring than many online sources suggest.
Semaglutide slows how quickly your stomach empties. So in theory, it could affect how the contraceptive pill is absorbed.
But studies of both injected and oral semaglutide have looked at this directly, and found no clinically meaningful drop in contraceptive absorption. In one study, taking oral semaglutide with a combined pill containing ethinylestradiol and levonorgestrel didn't affect how much of either hormone was absorbed.6
The FDA prescribing information notes that semaglutide's effect on stomach emptying could affect how other oral medicines are absorbed, and recommends monitoring medicines where small changes in level matter a lot. Based on the evidence, the contraceptive pill isn't considered one of these, and no dose change is recommended.
Any specific worries about semaglutide and your contraception? Speak to your GP or prescribing clinician. Losing weight can also affect fertility for some women, which is worth discussing with your doctor separately.
Are Wegovy semaglutide tablets available in the UK?
Wegovy semaglutide tablets were approved by the MHRA on 11 June 2026. For the latest on availability through Pharmica, visit our Wegovy tablets page.
NHS availability will take longer. NICE needs to complete a separate appraisal before the tablets can be prescribed on the NHS. This usually takes six to twelve months, so NHS access is more likely from 2027.
One important detail if you're already on the Wegovy injection. The MHRA has confirmed that people treated privately with the 2.4mg weekly injection can switch straight to the 25mg daily tablet, without going through the dose increases again.
So you don't need to restart from 1.5mg. You can move directly to the maintenance tablet dose under clinical supervision. Speak to your prescribing clinician if you're thinking about switching.
Who could be eligible for Wegovy semaglutide tablets?
The UK licence for Wegovy semaglutide tablets covers adults with obesity (a BMI of 30 or above), or overweight (a BMI of 27 to 30) with at least one weight-related health condition, like high blood pressure, high cholesterol or type 2 diabetes. That's the same as the UK criteria for the Wegovy injection.
You'll need a full clinical assessment before starting any semaglutide treatment. Tell your prescriber if you or a family member has had a rare thyroid cancer (medullary thyroid carcinoma) or multiple endocrine neoplasia type 2, so they can take this into account. Semaglutide tablets aren't recommended during pregnancy or breastfeeding.
Weight management options available through Pharmica include Wegovy injectable pens, Mounjaro (tirzepatide) and orlistat.
Have type 2 diabetes and take insulin or a sulfonylurea? Your prescriber may need to adjust them to avoid low blood sugar.
When to seek further advice
Contact your GP or prescribing clinician if you:
- Experience severe or persistent abdominal pain, particularly pain radiating to the back
- Develop signs of pancreatitis: sudden severe upper abdominal pain alongside nausea and vomiting
- Notice significant changes in your heart rate (palpitations or a rapid resting pulse)
- Develop symptoms of gallbladder disease: upper right abdominal pain, especially after eating fatty foods
- Are experiencing side effects that make it difficult to continue treatment
- Are unsure whether semaglutide tablets interact with other medications you're taking, including contraceptives
Frequently asked questions
What are Wegovy semaglutide tablets?
Wegovy semaglutide tablets are a once-daily oral weight loss treatment containing semaglutide, the same active ingredient as the Wegovy injection. They're manufactured by Novo Nordisk and represent the first oral GLP-1 receptor agonist licensed specifically for weight management. The tablet is taken once a day on an empty stomach and works in the same way as the injection: by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and help you feel fuller for longer.
Do Wegovy semaglutide tablets work for weight loss?
Yes, the clinical evidence is strong. In the phase 3 OASIS 4 trial, adults taking oral semaglutide 25mg daily lost an average of 13.6% of their body weight over 64 weeks, rising to 16.6% in those who completed the full course of treatment. Around one in three participants in the adherent group achieved at least 20% body weight loss. These results are broadly comparable to the standard 2.4mg Wegovy injection, making Wegovy semaglutide tablets one of the most effective oral weight loss treatments studied to date.
Are Wegovy semaglutide tablets as effective as the injection?
Broadly yes, though the injection has a modest advantage in average weight loss figures. The OASIS 4 trial found 16.6% average weight loss with the tablet (in adherent patients), while the STEP 1 trial of the 2.4mg Wegovy injection showed 14.9% and the higher-dose 7.2mg injection achieved 20.7%. However, the trials used different protocols and can't be directly compared. The tablet's real advantage is practical: it removes needles, cold-chain storage, and injection anxiety entirely, making semaglutide treatment accessible to more people.
When will Wegovy semaglutide tablets be available in the UK?
Wegovy semaglutide tablets were approved by the MHRA on 11 June 2026. Private prescription availability through regulated UK pharmacies is expected to follow within weeks of approval. NHS availability will take longer. NICE will need to complete a separate health technology appraisal before the tablets can be prescribed through the NHS. This process typically takes six to twelve months, making NHS access more realistic from 2027.
How do you take Wegovy semaglutide tablets?
Wegovy semaglutide tablets must be taken first thing in the morning, on a completely empty stomach, with no more than 120ml (roughly half a glass) of plain water. You then need to wait at least 30 minutes before eating, drinking anything other than water, or taking any other oral medication. The SNAC absorption technology in the tablet is disrupted by food or large volumes of liquid, which can significantly reduce how much semaglutide reaches your bloodstream. Swallow the tablet whole; don't crush, split, or chew it.
Can I take Wegovy semaglutide tablets at night instead of in the morning?
The approved protocol specifies taking the tablet first thing in the morning before any food or drink. This is primarily because the fasting requirement is easiest to achieve reliably on waking, and because it ensures consistent absorption conditions each day. Taking the tablet at night is technically possible only if you can guarantee a fully empty stomach, typically several hours after your last meal and with no food or drink until 30 minutes after the tablet. In practice, morning dosing is strongly recommended and the approach used in all clinical trials.
How long do Wegovy semaglutide tablets take to work?
Most people notice some reduction in appetite within the first few weeks, though meaningful weight loss typically becomes apparent over the first one to two months. The dose escalation schedule, which starts at 1.5mg and works up to the 25mg maintenance dose over around three months, means the full therapeutic effect builds gradually. In the OASIS 4 trial, weight loss continued to accumulate across the full 64-week treatment period. Results vary between individuals based on starting weight, dose adherence, and lifestyle changes alongside treatment.
How much will Wegovy semaglutide tablets cost in the UK?
UK pricing has not been confirmed yet. Novo Nordisk will publish a list price when the tablet commercially launches, expected within weeks of the 11 June 2026 MHRA approval. Private prescription pricing and availability updates will be published on the Wegovy oral tablet page as soon as they are confirmed.
Is the Wegovy semaglutide tablets the same as Rybelsus or Ozempic?
All three contain semaglutide, but they're different products with different licensed uses. Rybelsus is an oral semaglutide tablet licensed in the UK for type 2 diabetes only, at doses up to 9mg. It's not licensed or adequately dosed for weight management. Ozempic is an injectable semaglutide pen also licensed for type 2 diabetes. Wegovy semaglutide tablets are a higher-dose oral formulation (up to 25mg) specifically developed and licensed for weight management. They were approved by the MHRA in the UK on 11 June 2026 and are expected to be available by private prescription within weeks. Using Rybelsus off-label for weight loss isn't the same as using the properly dosed Wegovy semaglutide tablet.
Does the Wegovy semaglutide tablets affect the contraceptive pill?
Clinical studies suggest it doesn't. Although semaglutide slows gastric emptying, which in theory could affect how oral medications are absorbed, pharmacokinetic trials of both oral and injectable semaglutide found no clinically meaningful reduction in the absorption of ethinylestradiol or levonorgestrel, the hormones in most combined oral contraceptives. The FDA prescribing information notes a general potential for semaglutide to interact with oral medications, but oral contraceptives aren't flagged as requiring dose adjustment. If you have specific concerns, speak to your GP or prescribing clinician.
Can you take anti-sickness tablets with Wegovy semaglutide tablets?
It depends on the specific medication. Common over-the-counter options like cyclizine or promethazine are generally considered compatible with semaglutide, but because Wegovy semaglutide tablets slow gastric emptying, any oral medication taken within 30 minutes of the tablet may have reduced absorption. Anti-sickness medication should ideally be taken at least 30 minutes after the Wegovy semaglutide tablet. For prescription anti-emetics or if nausea is severe or persistent, speak to your prescribing clinician before self-treating, as they may also be able to adjust your dose escalation schedule to help.
Are there other oral GLP-1 tablets available in the UK?
Yes. Foundayo (orforglipron), developed by Eli Lilly, was authorised by the MHRA on 10 August 2026 for weight management and type 2 diabetes, making the UK the first country in Europe to approve it. Unlike the Wegovy pill, Foundayo is a non-peptide, small-molecule medicine, which means it can be taken at any time of day without the fasting rules that apply to Wegovy tablets. It's prescription-only and not yet available to buy through Pharmica.
References
- Novo Nordisk. FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults. Press release. December 2025. novonordisk.com
- Buckley ST, et al. Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018;10(467):eaar7047. doi:10.1126/scitranslmed.aar7047
- Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). New England Journal of Medicine. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Wharton S, Freitas P, Hjelmesaeth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). The Lancet Diabetes & Endocrinology. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8
- Hausner H, et al. Effect of oral semaglutide on the pharmacokinetics of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Clinical Pharmacokinetics. 2021;60(3):361-371. doi:10.1007/s40262-020-00976-x
This article is intended for informational purposes only and does not replace professional medical advice. Always read the patient information leaflet supplied with your medication and speak to a healthcare professional if you have specific concerns.